Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ASC Therapeutics

ASC Therapeutics Doses First Patient with ASC618 Second-Generation Gene Therapy for Hemophilia A
From ASC Therapeutics
Via Business Wire
ASC Therapeutics Joins U.S. Consortium of Gene Therapy Partners Including the NIH and FDA to Accelerate Treatments for Rare Diseases
From ASC Therapeutics
Via Business Wire
ASC Therapeutics, U Mass Medical School, and the Clinic for Special Children Announce Podium Presentation of Safety and Efficacy in Murine and Bovine Models for Novel Gene Therapy in Maple Syrup Urine Disease at the 25th ASGCT Meeting
From ASC Therapeutics
Via Business Wire
ASC Therapeutics Announces Podium and Poster Presentations of IND-Enabling Studies for ASC618, a Second-Generation Gene Therapy for Hemophilia A, at the 25th ASGCT Meeting, May 16-19, 2022 in Washington, D.C.
From ASC Therapeutics
Via Business Wire
ASC Therapeutics Receives Key Regulatory Designations in U.S. and Europe to Advance its Second-Generation Gene Therapy for Hemophilia A
From ASC Therapeutics
Via Business Wire
ASC Therapeutics and Professor Steven W. Pipe Publish Expert Review on Novel Gene Therapies of Hemophilia A
From ASC Therapeutics
Via Business Wire
ASC Therapeutics Appoints Gene and Cell Therapy Manufacturing Veteran Gary Potter to lead Global Operations
From ASC Therapeutics
Via Business Wire
ASC Therapeutics Announces Partnership With University of Massachusetts Medical School to Co-Develop Novel Gene Therapy for Maple Syrup Urine Disease
From ASC Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.